All In Biotech

Drug Trial Radar · NCT05690386

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner Syndrome

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Feb 15, 2023

Primary completion

Oct 18, 2024

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jan 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 1 year, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 104 week dose finding open label trial followed by an optional 78 week open label extension of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 individuals (12 individuals per arm) will be randomized to receive one of three doses of lonapegsomatropin or a daily injection of somatropin. This is a trial that will be conducted in the United States.

Conditions

  • Turner Syndrome

Interventions

  • LonapegsomatropinBiological

    Once-weekly subcutaneous injection of Lonapegsomatropin

  • SomatropinDrug

    Once-daily subcutaneous injection of Somatropin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Height Velocity (AHV) (cm/year)Time frame: 26 weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Palo Alto, California

  • Ascendis Pharma Investigational Site

    San Diego, California

  • Ascendis Pharma Investigational Site

    Aurora, Colorado

  • Ascendis Pharma Investigational Site

    Orlando, Florida

  • Ascendis Pharma Investigational Site

    St. Petersburg, Florida

  • Ascendis Pharma Investigational Site

    Atlanta, Georgia

  • Ascendis Pharma Investigational Site

    Idaho Falls, Idaho

  • Ascendis Pharma Investigational Site

    Chicago, Illinois

  • Ascendis Pharma Investigational Site

    Boston, Massachusetts

  • Ascendis Pharma Investigational Site

    Saint Paul, Minnesota

  • Ascendis Pharma Investigational Site

    Las Vegas, Nevada

  • Ascendis Pharma Investigational Site

    Lake Success, New York

  • Ascendis Pharma Investigational Site

    Chapel Hill, North Carolina

  • Ascendis Pharma Investigational Site

    Cincinnati, Ohio

  • Ascendis Pharma Investigational Site

    Oklahoma City, Oklahoma

  • Ascendis Pharma Investigational Site

    Portland, Oregon

  • Ascendis Pharma Investigational Site

    El Paso, Texas

  • Ascendis Pharma Investigational Site

    Fort Worth, Texas

  • Ascendis Pharma Investigational Site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.